Study no. IgPro20-3003: Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chro

Project: Research project

Project Details

Effective start/end date12/11/1212/11/15


  • ICON Clinical Research, LLC (Study no. IgPro20-3003)
  • CSL Behring (Study no. IgPro20-3003)